Literature DB >> 15317907

Catecholamine metabolism: a contemporary view with implications for physiology and medicine.

Graeme Eisenhofer1, Irwin J Kopin, David S Goldstein.   

Abstract

This article provides an update about catecholamine metabolism, with emphasis on correcting common misconceptions relevant to catecholamine systems in health and disease. Importantly, most metabolism of catecholamines takes place within the same cells where the amines are synthesized. This mainly occurs secondary to leakage of catecholamines from vesicular stores into the cytoplasm. These stores exist in a highly dynamic equilibrium, with passive outward leakage counterbalanced by inward active transport controlled by vesicular monoamine transporters. In catecholaminergic neurons, the presence of monoamine oxidase leads to formation of reactive catecholaldehydes. Production of these toxic aldehydes depends on the dynamics of vesicular-axoplasmic monoamine exchange and enzyme-catalyzed conversion to nontoxic acids or alcohols. In sympathetic nerves, the aldehyde produced from norepinephrine is converted to 3,4-dihydroxyphenylglycol, not 3,4-dihydroxymandelic acid. Subsequent extraneuronal O-methylation consequently leads to production of 3-methoxy-4-hydroxyphenylglycol, not vanillylmandelic acid. Vanillylmandelic acid is instead formed in the liver by oxidation of 3-methoxy-4-hydroxyphenylglycol catalyzed by alcohol and aldehyde dehydrogenases. Compared to intraneuronal deamination, extraneuronal O-methylation of norepinephrine and epinephrine to metanephrines represent minor pathways of metabolism. The single largest source of metanephrines is the adrenal medulla. Similarly, pheochromocytoma tumor cells produce large amounts of metanephrines from catecholamines leaking from stores. Thus, these metabolites are particularly useful for detecting pheochromocytomas. The large contribution of intraneuronal deamination to catecholamine turnover, and dependence of this on the vesicular-axoplasmic monoamine exchange process, helps explain how synthesis, release, metabolism, turnover, and stores of catecholamines are regulated in a coordinated fashion during stress and in disease states.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15317907     DOI: 10.1124/pr.56.3.1

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  249 in total

1.  Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2.

Authors:  Jiri Petrak; Jana Pospisilova; Miroslava Sedinova; Petr Jedelsky; Lucie Lorkova; Ondrej Vit; Michal Kolar; Hynek Strnad; Jan Benes; David Sedmera; Ludek Cervenka; Vojtech Melenovsky
Journal:  Proteome Sci       Date:  2011-11-11       Impact factor: 2.480

Review 2.  Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Authors:  Thamara E Osinga; Thera P Links; Robin P F Dullaart; Karel Pacak; Anouk N A van der Horst-Schrivers; Michiel N Kerstens; Ido P Kema
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

Review 3.  Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases.

Authors:  David S Goldstein
Journal:  Cell Mol Neurobiol       Date:  2012-07       Impact factor: 5.046

4.  Sulfation of ractopamine and salbutamol by the human cytosolic sulfotransferases.

Authors:  Kyounga Ko; Katsuhisa Kurogi; Garrett Davidson; Ming-Yih Liu; Yoichi Sakakibara; Masahito Suiko; Ming-Cheh Liu
Journal:  J Biochem       Date:  2012-07-04       Impact factor: 3.387

5.  Catechols in post-mortem brain of patients with Parkinson disease.

Authors:  D S Goldstein; P Sullivan; C Holmes; I J Kopin; M J Basile; D C Mash
Journal:  Eur J Neurol       Date:  2010-11-12       Impact factor: 6.089

6.  Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis.

Authors:  Lina Yao; Peidong Fan; Maria Arolfo; Zhan Jiang; M Foster Olive; Jeff Zablocki; Hai-Ling Sun; Nancy Chu; Jeongrim Lee; Hee-Yong Kim; Kwan Leung; John Shryock; Brent Blackburn; Ivan Diamond
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

7.  Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats.

Authors:  Megan M Kangiser; Linda P Dwoskin; Guangrong Zheng; Peter A Crooks; Dustin J Stairs
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

8.  6-[18F]fluoro-L-DOPA uptake in the rat pancreas is dependent on the tracer metabolism.

Authors:  Teemu Kalliokoski; Johanna Tuomela; Laura Haavisto; Sarita Forsback; Anniina Snellman; Semi Helin; Tove J Grönroos; Olof Solin; Merja Haaparanta-Solin
Journal:  Mol Imaging Biol       Date:  2013-11-12       Impact factor: 3.488

9.  A Clinical Trial Simulation Evaluating Epinephrine Pharmacokinetics at various Dosing Frequencies during Cardiopulmonary Resuscitation.

Authors:  Andy R Eugene
Journal:  MEDtube Sci       Date:  2016-06-30

Review 10.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.